info:eu-repo/semantics/article
A novel fission yeast platform to model N -glycosylation and the bases of congenital disorders of glycosylation Type I
Fecha
2022-03Registro en:
Gallo, Giovanna Lucrecia; Valko, Ayelén; Herrera Aguilar, Nathalia; Weisz, Ariel D.; D'alessio, Cecilia; A novel fission yeast platform to model N -glycosylation and the bases of congenital disorders of glycosylation Type I; Company of Biologists; Journal of Cell Science; 135; 5; 3-2022; 1-13
0021-9533
1477-9137
CONICET Digital
CONICET
Autor
Gallo, Giovanna Lucrecia
Valko, Ayelén
Herrera Aguilar, Nathalia
Weisz, Ariel D.
D'alessio, Cecilia
Resumen
Congenital disorders of glycosylation type I (CDG-I) are inherited human diseases caused by deficiencies in lipid-linked oligosaccharide (LLO) synthesis or the glycan transfer to proteins during N-glycosylation. We constructed a platform of 16 Schizosaccharomyces pombe strains that synthesize all possible theoretical combinations of LLOs containing three to zero glucose (Glc) residues and nine to five mannose (Man) residues. The occurrence of unexpected LLOs suggested the requirement of specific Man residues for glucosyltransferase activities. We then quantified protein hypoglycosylation in each strain and found that in S. pombe the presence of Glc in the LLO is more relevant to the transfer efficiency than the number of Man residues. Surprisingly, a decrease in the number of Man residues in glycans somehow improved the glycan transfer. The most severe hypoglycosylation was produced in cells that synthesized LLOs completely lacking Glc and having a high number of Man residues. This deficiency could be reverted by expressing a single-subunit oligosaccharyltransferase with a broad range of substrate specificity. Our work shows the usefulness of this new S. pombe set of mutants as a platform to model the molecular bases of human CDG-I diseases. This article has an associated First Person interview with the first authors of the paper.